Precious Cells

What Precious Cells does

Precious Cells International is a London-based, privately held stem cell banking company founded in 2008 that offers direct-to-consumer cryopreservation and storage services across five tissue source categories: cord blood, cord tissue, dental pulp, adipose tissue, and bone marrow. The company serves three customer segments — expectant parents seeking newborn banking, adults interested in personal biobanking (for example, adipose or bone marrow), and healthcare professionals — through a consumer-facing go-to-market model. It holds 35 unique Human Tissue Authority (HTA) licenses under HTA #22615 and is described as the only UK biobank licensed for LipoTissue.

The company's technical platform is built around a patented processing system and proprietary handling methods, including the "Precious Tooth" dental pulp extraction technique — the first of its kind in the UK. It operates the Precious Cells Training Institute and partners with Brunel University London for laboratory facilities. A Scientific Advisory Board comprising professors from Barts, Imperial College London, and the University of Leicester provides clinical and academic credibility. The company received industry recognition in 2013 with awards for "Best Biotechnology" and "Most Innovative in Stem Cell Storage."

Revenue mechanics are based on consumer enrollment and long-duration storage contracts with individual families; pricing is not publicly disclosed. The company is bootstrapped with no disclosed funding rounds and operates with a leadership and management team of approximately 15 people. The breadth of tissue types processed, the regulatory license portfolio, and the proprietary techniques together define the operating scope; the company has not disclosed enterprise customers, contract values, or revenue figures.

Name

Precious Cells

Legal name

Precious Cells International

Website

https://precious-cells.com

Company type

Private

Founded year

2008

Operating status

Operating

Short description

Precious Cells International is a London-based, privately held stem cell biobank founded in 2008 that offers direct-to-consumer cryopreservation across five tissue sources. It serves expectant parents, adults, and healthcare professionals and holds 35 UK HTA licenses.

Ownership category

akta.pro rank

Product category

Stem Cell Banking Services

NAICS

Blood and Organ Banks (621991)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

akta.pro secondary industries

Cryopreservation, Biobanking & Cell Banking (Cord/Adipose/MSC) (HLAMANAJ), Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ)

Keywords

• Stem cell banking
• Cord blood storage
• Dental pulp banking
• Cryopreservation services
• Regenerative medicine

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Stem Cell Banking Services: One-time collection fees combined with ongoing storage fees for stem cells preserved for personal family use. Customers pay for collection services at birth or through dental/or surgical procedures, then pay storage fees for maintaining cells over time (up to 30 years or more).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Precious Cells is a stem cell biobank that collects, processes, and cryopreserves biological samples from five sources — umbilical cord blood, umbilical cord tissue, dental pulp (from extracted teeth), adipose tissue (via liposuction), and bone marrow — for private family storage. Customers contract for an upfront collection/processing service and then pay ongoing storage fees to keep the cryopreserved sample available for potential future therapeutic use, with advertised storage of 30+ years.

Product overview

Precious Cells is a premium family autologous stem cell biobank offering five distinct stem cell collection and cryopreservation services: Precious Cord Blood (umbilical cord blood stem cells), Precious Cord Tissue (umbilical cord tissue stem cells), Precious Teeth (dental pulp stem cells from teeth), Precious Lipo (adipose/fat tissue stem cells), and Precious Marrow (bone marrow stem cells). The company operates its own purpose-built cleanroom laboratory at Brunel University, London, and was the first company in the world to develop techniques for storing stem cells from dental pulp and the only UK biobank licensed to collect, process and store LipoTissue. Services are targeted at families seeking to preserve stem cells from multiple sources for potential future medical treatment of conditions including blood disorders, immune system diseases, and regenerative medicine applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Precious Cord Blood

Quantifiable outcome

• 1 in 200 chance of needing stem-cell transplant in lifetime
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Brunel University LondoncoreStrategic or Co-development PartnerPrecious Cells operates its purpose-built cleanroom laboratory at Brunel University, London. The company states it works in collaboration with one of the UK's leading universities ensuring continual development of all services and processes.
• International Stem Cell Treatment CentresminorStrategic or Co-development PartnerPrecious Cells maintains strong international affiliations to guide customers to the world's leading stem-cell treatment centres should they need to use their stored stem cells.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Regional players

• LifeCell International: India-based stem cell banking and tissue storage provider. Comparable family autologous storage model in a different geography, useful for regional benchmarking of consumer biobanking economics.
• China Cord Blood Corporation: Largest operator of cord blood banks in China with a partially consumer-facing storage model. Comparable category with vastly larger scale and an Asian regulatory and customer base.

Broad incumbents

• Cord Blood Registry (CBR): Largest US cord blood bank and broader incumbent in family stem cell storage. Overlapping autologous storage proposition but with significantly larger scale, brand recognition, and hospital network.
• Cryo-Cell International: US-listed cord blood bank with multi-decade operating history and consumer-facing storage services. Comparable autologous family banking model, with significantly greater capital base and US distribution.
• ViaCord: Established US-based family cord blood and cord tissue bank. Comparable service category (private family storage) with broader awareness and longer operating history than Precious Cells.

Direct peers

• Future Health Biobank: UK-based stem cell and tissue storage biobank with international collection footprint. Directly comparable service offering (cord blood, cord tissue, and broader samples) and HTA-regulated operating model.
• Smart Cells International: UK-based cord blood banking service offering collection and storage for families globally. Competes directly with Precious Cells on the same cord blood/tissue storage proposition to expectant parents.
• Cells4Life: UK-based private stem cell biobank offering cord blood and cord tissue storage to families. Direct competitor in the UK consumer autologous banking segment with a comparable direct-to-consumer go-to-market.
• Cryo-Save (Esperite): European family stem cell storage company operating across multiple countries. Comparable consumer autologous biobank model with multi-source storage and recurring storage revenue, though larger geographic scale.

Emerging players

• Biovault Family: UK-based family cord blood and tissue storage provider. Smaller UK peer competing in the same consumer autologous storage category with comparable HTA-regulated operating model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/precious-cells-international-limited

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precious Cells